News

Researchers at Athens Medical School in Greece recently revealed that the drug buspirone offers clinical benefits to systemic sclerosis patients with esophageal dysfunction. The study was recently published in the United European Gastroenterology Journal and is entitled “Beneficial effect of the 5-HT1A receptor…

Patients in the LOTUSS study who were treated for systemic sclerosis-associated idiopathic pulmonary fibrosis (SSc-IPF) using Esbriet (pirfenidone) showed signs of drug tolerability, according to a presentation at the European League Against Rheumatism (EULAR) 2015 congress held in Rome. Esbriet, which was approved by the Food and…

Digital ulcers, or open sores on the fingers and toes that do not heal, are common complications of systemic sclerosis. Approximately 30% of patients with systemic sclerosis have digital ulcers, most commonly on the fingertips or on the elbows due to taut skin or trauma. These painful sores can lead…

In a recent study published in the Journal of Clinical Investigation, a team of researchers from the Boston University School of Medicine (BUSM) discovered a treatment breakthrough for total body scarring of the skin that occurs in patients with systemic sclerosis (SSc). The condition for which currently there…

In a recent study published in the journal Arthritis Research & Therapy, a team of researchers from Germany uncovered new insights into PAH detection in Scleroderma patients, determining that PH-screening using echocardiography in systemic sclerosis patients should be performed at rest and during exercise. Pulmonary hypertension (PH) is…

Autoimmune conditions can sometimes come in pairs, and it appears that individuals for systemic sclerosis (SSc) may also be at a risk for antiphospholipid antibody syndrome. A study from the Clinical Immunology Department of Colentina Clinical Hospital in Romania identified that patients with SSc commonly express antiphospholipid antibodies, although not…

According to a study recently presented at the Annual European Congress of Rheumatology (EULAR), Rome, patients with systemic sclerosis harbor a unique microbiome in their gut when compared to healthy individuals, which may contribute to patients’ immune dysfunction. Systemic sclerosis, also known as scleroderma, is an autoimmune disease (autoimmune diseases…

A investigational drug being developed by Corbus Pharmaceuticals Holding, Inc. to treat systemic sclerosis was granted orphan drug designation by the U.S. Food and Drug Administration (FDA). The drug that received the status, resunab, is Corbus’ lead drug candidate, as the company is focused on…

A study recently presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, Italy, June 10-13 revealed that individuals with systemic sclerosis have a unique bacterial signature in their colon that is different from healthy individuals. Systemic sclerosis, also known as scleroderma, is a rare, chronic…

It’s a breakthrough: Roche has been awarded breakthrough therapy designation status for its ACTEMRA®/RoACTEMRA® (tocilizumab) treatment in patients with systemic sclerosis. The designation will enable Roche to speed up development and review of its treatment to help bring systemic sclerosis patients this new treatment as soon as possible. “Close to…